Announcing the development of MC4R agonist drug candidates demonstrating the potential to transform GLP1 obesity therapy
“This synergy between the MC4R circuit and GLP1RA agents could revolutionize the obesity treatment landscape similar to how GLP1/GIP combinations such as tirzepatide have recently shown dramatic improvements in weight loss.” said Dan Housman CEO.